Company News for November 24, 2010 - Corporate Summary

• Eli Lilly (NYSE:LLY) received FDA approval for its topical solution drug Axiron, for testosterone replacement therapy in men

• Tiffany (NYSE:TIF) reported estimate-beating third quarter earnings of $0.43 a share, ahead of Zacks projections of $0.37, on a 14% revenue jump to $681.7 million that was above Zacks estimates of $651 million. The firm said it sees current year earnings of $2.72 to $2.77 a share

• Deere (NYSE:DE) reported better-than-anticipated fiscal fourth quarter earnings of $1.07, up from Zacks estimates of $0.96, as revenues rose 38.9% to $6.56 billion, below Zacks projections of $6.66 billion

• Oracle (NASDAQ:ORCL) received a jury award of $1.3 billion in its suit against SAP (NYSE:SAP)

• FBR reiterated its “underperform” rating on Diamond Offshore (NYSE:DO), with a price target of $56

• JP Morgan (NYSE:JPM) downgraded Rovi (NASDAQ:ROVI) from “overweight” to “neutral,” with a price target of $65

• FBR maintained a “market perform” on Jefferies (NYSE:JEF), with a price target of $25

• Wells Fargo (NYSE:WFC) initiated coverage of Tower International (NYSE:TOWR) at “outperform,” with a price target range of $16-$18

• Goldman Sachs (NYSE:GS) started coverage of Bemis (NYSE:BMS) at “neutral,” with a price target of $35

Company News for November 24, 2010 – Corporate Summary

SIGN UP TO NEWSLETTER

Free E-Book

Recent Posts